Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 study will assess the efficacy and safety of potentially the first subcutaneous long-acting Injectable (LAI) formulation of olanzapine (mdc-TJK) for the treatment of patients with schizophrenia

Next Previous
X
Search
Trial Profile

A phase 3 study will assess the efficacy and safety of potentially the first subcutaneous long-acting Injectable (LAI) formulation of olanzapine (mdc-TJK) for the treatment of patients with schizophrenia

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Feb 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olanzapine (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use

    • Most Recent Events

    • 31 Jan 2024 According to a MedinCell S.A. media release, 62% of the targeted 3,600 injections have already been performed as part of this study and no PDSS has been observed.
    • 08 Nov 2023 According to a MedinCell S.A. media release, results expected in the second half of 2024.
    • 02 Aug 2023 According to a MedinCell S.A. media release, this trial has been initiated in January 2023 and is enrolling very quickly.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top